Role of T-cell-specific nuclear factor κb in islet allograft rejection

Transplantation

Volumn 93, Issue 10, 2012, Pages 976-982

  Porras, Delia Lozano ^a   Wang, Ying ^a   Zhou, Ping ^a   Molinero, Luciana L ^a   Alegre, Maria Luisa ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Islet transplantation; NF B; T cells

Indexed keywords

B LYMPHOCYTE RECEPTOR; CELL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; PROTEIN CARMA1; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL SPECIFICITY; CONTROLLED STUDY; ENGRAFTMENT; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOFLUORESCENCE TEST; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; KNOCKOUT MOUSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN TARGETING; SKIN TRANSPLANTATION; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CARD SIGNALING ADAPTOR PROTEINS; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE TOLERANCE; ISLETS OF LANGERHANS TRANSPLANTATION; ISOANTIGENS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NF-KAPPA B; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84862797089     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31824d11d7     Document Type: Article

References (30)

1. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
2. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
3. Boothby MR, Mora AL, Scherer DC, et al. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-kappaB. J Exp Med 1997; 185: 1897.
4. Aronica MA, Mora AL, Mitchell DB, et al. Preferential role for NFkappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol 1999; 163: 5116.
5. Mora A, Youn J, Keegan A, et al. NF-kappa B/Rel participation in the lymphokine-dependent proliferation of T lymphoid cells. J Immunol 2001; 166: 2218.
6. Corn RA, Aronica MA, Zhang F, et al. T cell-intrinsic requirement for NFkappa B induction in postdifferentiation IFN-gamma production and clonal expansion in a Th1 response. J Immunol 2003; 171: 1816.
7. MoraAL,CornRA, Stanic AK, et al. Antiapoptotic function ofNF-kappaB in T lymphocytes is influenced by their differentiation status: Roles of Fas, c-FLIP, and Bcl-xL. Cell Death Differ 2003; 10: 1032.
8. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17.
9. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693.
10. Thome M, Charton JE, Pelzer C, et al. Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2010; 2: A003004.
11. Yang H, Thomas D, Boffa DJ, et al. Enforced c-REL deficiency prolongs survival of islet allografts1. Transplantation 2002; 74: 291.
12. Egawa T, Albrecht B, Favier B, et al. Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation. Curr Biol 2003; 13: 1252.
13. Stanic AK, Bezbradica JS, Park JJ, et al. NF-kappa B controls cell fate specification, survival, and molecular differentiation of immunoregulatory natural T lymphocytes. J Immunol 2004; 172: 2265.
14. Zhou P, Hwang KW, Palucki DA, et al. Impaired NF-kB activation in T cells permits tolerance to primary heart allografts and to secondary donor skin grafts. Am J Transplant 2003; 3: 139.
15. Finn PW, Stone JR, Boothby MR, et al. Inhibition of NF-kappaBdependent T cell activation abrogates acute allograft rejection. J Immunol 2001; 167: 5994.
16. Chen L, Wang T, Zhou P, et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006; 6: 2282.
17. Alegre ML, Goldstein DR, Chong AS. TLR signaling in transplantation. Curr Opin Organ Transplant 2009; 13: 358.
18. Walker WE, Nasr IW, Camirand G, et al. Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol 2006; 177: 5307.
19. McKay D, Shigeoka A, Rubinstein M, et al. Simultaneous deletion of MyD88 and Trif delays major histocompatibility and minor antigen mismatch allograft rejection. Eur J Immunol 2006; 36: 1994.
20. Locksley RM, Pingel S, Lacy D, et al. Susceptibility to infectious diseases: Leishmania as a paradigm. J Infect Dis 1999; 179: S305.
21. Zhou P, Balin SJ, Mashayekhi M, et al. Transplantation tolerance in NFkappaB- impaired mice is not due to regulation but is prevented by transgenic expression of Bcl-xL. J Immunol 2005; 174: 3447.
22. Molinero LL, Wang Y, Zhou P, et al. Fas mediates cardiac allograft acceptance in mice with impaired T cell-intrinsic NF-kB signaling. Transpl Int 2009; 22: 845.
23. Kupfer T, Beilke JN, Pham K, et al. ''Indirect'' acute islet allograft destruction in nonobese diabetic mice is independent of donor major histocompatibility complex and requires host B lymphocytes. Transplant Proc 2008; 40: 462.
24. Molinero L, Zhou P, Wang Y, et al. Epidermal Langerhans cells play a major role in skin allograft rejection in mice with NF-kB-impaired T cells. Am J Transplant 2008; 8: 21.
25. Brenner D, Brechmann M, Rohling S, et al. Phosphorylation of CARMA1 by HPK1 is critical for NF-kappaB activation in T cells. Proc Natl Acad Sci USA 2009; 106: 14508.
26. Thome M, Weil R. Post-translational modifications regulate distinct functions of CARMA1 and BCL10. Trends Immunol 2007; 28: 281.
27. Chao DT, Linette GP, Boise LH, et al. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med 1995; 182: 821.
28. Hsieh CS, Macatonia SE, O'Garra A, et al. T cell genetic background determines default T helper phenotype development in vitro. J ExpMed 1995; 181: 713.
29. Ehst BD, Ingulli E, Jenkins MK. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am J Transplant 2003; 3: 1355.
30. Firpo EJ, Kong RK, Zhou Q, et al. Antigen-specific dose-dependent system for the study of an inheritable and reversible phenotype in mouse CD4+ T cells. Immunology 2002; 107: 480.